Christian read Politics, Philosophy and Economics at Lincoln College, Oxford.  His career started at the Boston Consulting Group where he worked both in Europe and the US. He then moved to the UK Holding Company a subsidiary of the German/Dutch Conglomerate, Hoogovens/Hoechst as a director of two of their subsidiaries in the UK, winning the Queen’s award for Exports in one of those subsidiaries. He then became Vice President of Fox Pitt Kelton, where he worked on the mergers and acquisitions of US Regional Banks.  Subsequently, Christian embarked on career in venture capital, initially in conjunction with Ensign Trust PLC, owned by the Merchant Navy Pension Fund.  Christian founded Oxford BioDynamics in 2007 with Dr. Alexandre Akoulitchev and Dr. Aroul Ramadass.  Christian was the Chairman of both Chronos Therapeutics Limited and Sibelius Limited until August 2016, at which point he stepped down from both roles.   He is now a Non-Executive Director of both Chronos Therapeutics Limited and Sibelius Limited. Christian sits on the Nominations Committee.

Alexandre Akoulitchev

Alexandre read mathematics, physics, chemistry, biochemistry and biophysics at Moscow Institute of Physics and Technology.  In 1989 he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students from the USSR. He obtained his PhD in cell biology from University College, London (with the research based at the Imperial Cancer Research Fund). He spent six years at the Robert Wood Johnson Medical School-UMDNJ, NJ, as a research assistant funded by the Howard Hughes Medical Institute. Upon his return to England, he established his research laboratory at the Sir William Dunn School of Pathology, University of Oxford.  He was a University Academic Fellow (Research Council UK) and a Senior Fellow of Exeter College, sponsored by Cancer Research UK, the Wellcome Trust, The Medical Research Council and Monsanto Foundation.  Alexandre is also a Fellow of the Royal Society of Medicine.  He is currently a Non-Executive Director of Sibelius Limited.

Aroul read molecular biology and biotechnology at the Indian Agricultural Research Institute, New Delhi, after obtaining National First in the All India Combined Entrance Exam. He was awarded the Felix and Cambridge Commonwealth Scholarships and read bioinformatics at Cambridge University and at the Wellcome Trust Sanger Institute (PhD awarded in 2004). Since then, Aroul worked with Dr. Alexandre Akoulitchev at the Sir William Dunn School of Pathology, Oxford University and is one of the founders of the Company, leading and managing the Oxford BioDynamics laboratory. Aroul developed the key pattern recognition software supporting the Company’s research and is a Fellow of Cambridge Commonwealth Society, Cambridge Philosophical Society and Royal Asiatic Society.

Paul joined the Company in September 2017 from e-Therapeutics plc, where he held the position of Financial Controller from 2012. Paul is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors.  He read Natural Sciences at St John’s College, University of Cambridge.

Martin has over 20 years’ experience in business development and strategic planning, including Teva Pharmaceuticals where he was Head of Business Development for Global Branded Products. He was previously Vice President of Business Development and Strategic Planning at Cephalon where, in his fourteen years at the company, he played a key role in defining the strategic direction for growth and diversification globally, including planning strategies to enter into new markets such as Asia. Cephalon was bought by Teva in 2011 for $6.8 billion.

Prior to joining Cephalon, Martin held project management roles at Wyeth-Ayerst and Smith Kline Beecham. Martin started his career as a Research Biochemist at Smith Kline & French and holds a degree in Biochemistry from London University.

Jayne read Biomedical Technology and later obtained a PhD in Molecular Biology from the University of Sheffield. She went on to become a Postdoctoral Fellow at the University of Leeds spending 10 years researching nematode resistance in a variety of crops. Subsequently, she moved away from academia into industry to lead the Gene Discovery team at Advanced Technologies Cambridge (a subsidiary of British American Tobacco) researching harm reduction in tobacco. Her next role was as Residue Manager at Oxford Agricultural Trials, working as the Principle Investigator for residue and soil dissipation studies. Jayne joined Oxford BioDynamics as the Laboratory Project Manager in 2015.

Lim read agricultural science with a major in agricultural chemistry from the Kyoto University, Japan, which he followed with a Masters and a PhD from Nara Institute of Science and Technology. His studies had been supported by multiple awards: the Monbusho (Ministry of Education, Sports and Culture, Japan) Scholarship (1989-1996); Sasakawa Fellowship (1996-1999); Young Researcher Fellowship of Nihon Kagaku Shinkokai (Japan Society for the Promotion of Science, JSPS) (1996-1999); and Kanagawa Prefecture Industrial Technology Development Award (2007). He started work at DNA Chip Research Inc. (Yokohama) in 1999 as a Senior Scientist where he was later promoted to R&D Group Manager. Before joining the Company, he was a General Manager at Gene News Diagnostics.

Els read Chemical Engineering and obtained an MBA at VUB University, Belgium. She has over 15 years of experience in clinical research and development, financial analysis, venture capital investments and financial management. She is an experienced dealmaker, with a knowledge base of venture capital and pre-IPO universe. Els has served on the board of directors of several companies and funds, including amongst others Capricorn Venture Fund II, Algonomics, 4AZA, Nexstim Oy, Sequana Medical and Sphere Medical. Currently she is on the board of Biogazelle. She was a key member of the team manageing the KBC ARKIV fund, an initiative aimed at SME’s and Quest for Growth, a Euronext listed closed-end fund. In her most recent position at QBIC Venture Partners, Belgium, Els has been actively involved in the creation and financing of spin-offs of the universities of Antwerp, Brussels and Ghent.

Ewan Hunter

Ewan’s first degree is in Biochemistry from Edinburgh University, after which he went to Guy’s & St Thomas Medical School, King’s College London to complete his PhD in Statistical Molecular Neurobiology. After completing his PhD, Ewan went on to work with MWG Biotechnology as Field Scientist for robotics and microarray technologies. In 2001 he joined Silicon Genetics as the European Technical Manager, where he helped establish GeneSpring as the primary tool for microarray analysis. After Agilent bought Silicon Genetics in 2004, he became the European Technical expert for high throughput data analysis. Ewan left Agilent in 2008 to join GeneGo Inc. (now Thompson Reuters) as their European Technical Sales Director. In 2010, Ewan joined Selventa Inc. as their European Technical Sales Director.

Francis is an enthusiastic post-doctoral Senior Technology Manager, his PhD studies were completed in the Department of Haematology at the Imperial College School of Medicine.

He has spent more than ten years in academic leukaemia research developing genetic tests for the NHS and commercial markets. As a Senior Research Fellow at the University of Southampton he received the Wellcome Trust Postdoctoral Career award. He has 37 peer reviewed papers in the field of molecular genetics and cell biology, and is an international member of the American Society of Hematology.

At Oxford Biodynamics the main focus of his work has been the conversion of the 3C nested PCR  tests to qPCR and the identification of 3C pharmacogenetic lesions. In is his spare time Francis is a ski instructor.

Emily received a BSc (Hons) in Biology from the Kingston University and then obtained an MSc in Forensic Science from the University of Teesside. She went on to become a Bioanalyst at a contract research laboratory before moving to LGC Forensics, where she became a Forensic Examiner in the biology department, where attention to detail is key. Emily joined Oxford Biodynamics in 2011 as a research scientist. She then progressed to RA/QA Manager in 2016 and is a member of the Research Quality Association.

Mehrnoush read cellular and molecular biology at Tehran University and then started to work as a pathologist at Shahid Beheshti hospital in Iran for one year. In 2011, she furthered her studies by obtaining a Master of Science degree in molecular medicine and cancer research at Brunel University London where she studied epigenetics in Friedreich ataxia patients and mouse models. She joined Oxford Biodynamics as a research technician in 2012 and continues to work as a project manager

Matthew read Molecular Biology at the University of Exeter graduating in 2010. He joined Oxford Biodynamics in 2012 as a lab technician, gaining experience and progressing in the company. Matthew is a Prince2 qualified project manager working alongside Dr Ewan Hunter in the analytics department.